Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Carboplatin
  • Carcinoma, Non-Small-Cell Lung
  • Cyclooxygenase Inhibitors
  • Lung Neoplasms
  • Paclitaxel
  • Sulfonamides

abstract

  • In comparison with historically reported response rates, these data suggest that the addition of a selective COX-2 inhibitor may enhance the response to preoperative paclitaxel and carboplatin in patients with NSCLC. Moreover, treatment with celecoxib 400 mg twice daily was sufficient to normalize the increase in PGE2 levels found in NSCLC patients after treatment with paclitaxel and carboplatin. Confirmatory trials are planned.

publication date

  • July 15, 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2003.07.127

PubMed ID

  • 12860939

Additional Document Info

start page

  • 2645

end page

  • 50

volume

  • 21

number

  • 14